---
title: "Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/271252034.md"
description: "Cathie Wood's ARK Invest is pivoting towards genomic stocks, anticipating a significant genomic revolution by 2026. The firm has sold off legacy stocks like Tesla to invest heavily in gene-editing companies such as CRISPR Therapeutics, Beam Therapeutics, and Pacific Biosciences. Wood emphasizes the synergy between AI and biology, predicting that advancements in AI will enhance gene sequencing and drug development. By late 2025, ARK's holdings in these companies will significantly increase within its flagship ARKK Innovation Fund and the Ark Genomic Revolution Fund."
datetime: "2025-12-31T22:06:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271252034.md)
  - [en](https://longbridge.com/en/news/271252034.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271252034.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/271252034.md) | [English](https://longbridge.com/en/news/271252034.md)


# Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

The massive rotation currently unfolding within **ARK Invest** suggests that **Cathie Wood** thinks 2026 will be the definitive coming-out party for the genomic revolution.

-   **PACB stock is up. See the chart and price action here.** 

As 2025 draws to a close, ARK aggressively trimmed legacy winners such as **Tesla, Inc.** (NASDAQ:TSLA) and **Rocket Lab Corp.** (NASDAQ:RKLB) to fund a multi-million dollar accumulation of gene-editing pioneers. 

**Read Next:** Palantir: From Meme Stock To Market Leader In 2025 

ARK Invest has been specifically loading up on shares of **CRISPR Therapeutics AG** (NASDAQ:CRSP), **Intellia Therapeutics, Inc.** (NASDAQ:NTLA), **Beam Therapeutics, Inc.** (NASDAQ:BEAM) and **Pacific Biosciences of California Inc.** (NASDAQ:PACB) heading into the end of the year. 

## **The Strategy**

Wood's thesis is built on the combination of artificial intelligence and programmable biology. Earlier this year, Wood highlighted the transformative potential of AI in health care, calling it the most profound application of artificial intelligence. 

According to Ark’s multiomics flywheel framework, AI accelerated all aspects of multiomics from generating biological data to diagnosing diseases and developing new drugs.

“Smarter algorithms make gene sequencing faster; cheaper sequencing gives AI more data to learn from; and breakthroughs in gene editing can open the door to new treatments,” Wood explained.

## **The Holdings**

By late December 2025, ARK increased its weight in CRISPR Therapeutics to over 5% of its flagship **ARKK Innovation Fund** (BATS:ARKK), Beam Therapeutics grew to 3.41% of ARKK, Twist accounted for 2% and Intellia was 1.14% of the same fund. 

Ark Invest also has the **Ark Genomic Revolution Fund** (BATS:ARKG) dedicated to investing in companies across sectors, including health care and information technology, that are relevant to the theme of the genomics revolution.

**Read Next:** 

-   Metals Acting Like Meme Stocks—Unconfirmed Rumor Of Major Silver Margin Call

_Photo: Shutterstock_

### 相關股票

- [CRISPR Therap (CRSP.US)](https://longbridge.com/zh-HK/quote/CRSP.US.md)

## 相關資訊與研究

- [Crispr Therapeutics Completes $600 Million Convertible Notes Offering](https://longbridge.com/zh-HK/news/279320685.md)
- [Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS](https://longbridge.com/zh-HK/news/278972107.md)
- [I spent 17 hours at a legal conference. These were the two questions haunting lawyers about AI.](https://longbridge.com/zh-HK/news/279116629.md)
- [Goldman Sachs sees a flight to quality in artificial intelligence (AI). This stock fits the bill for 2026.](https://longbridge.com/zh-HK/news/279128728.md)
- [How AI is changing the business and art of video — from ‘chaos machine’ to creative catalyst](https://longbridge.com/zh-HK/news/279129168.md)